The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable excitement within the healthcare community. This groundbreaking dual GIP and GLP-1 agonist medication seems to provide notable improvements in weight loss compared to previous therapies. Preliminary clinical data have shown marked decreases in body mass , poten